Back to search

Article

Exendin-4 alleviates hepatic steatosis by lowering FABP1 and raising FOXA1 expression via the Wnt/-catenin signaling pathway

2021-09-23

Abstract excerpt

Non-alcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Agonists of the glucagon-like peptide-1 receptor (GLP-1R), currently approved to treat type 2 diabetes, hold promise to improve steatosis and even steatohepatitis. However, due to their pleiotropic effects, the mechanisms underlying their protective effect on NAFLD remain elusive. We aimed to investigate these mechanisms usin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
50e6f832-c492-519e-9235-82fff86d20b4
DOI
10.21203/rs.3.rs-898584/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Exendin-4 alleviates hepatic steatosis by lowering FABP1 and raising FOXA1 expression via the Wnt/-catenin signaling pathwayDOI 10.21203/rs.3.rs-898584/v1
Select a neighboring publication to make it the new centre.